Anheuser-Busch InBev SA/NV · BUD · FY2025 Q2 · Calendar Q3 2025
AB InBev: Premium brands and digital growth offset softer volumes
The supplied Q2 analysis supports a qualified growth-through-premiumization thesis: premium and non-alcohol brands and BEES are growing, while declining volumes and weakness in China and Brazil leave the durability of earnings growth uncertain.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about BUD FY2025 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the supplied Q1 analysis, Q2 retained EBITDA growth and margin expansion but showed slower EBITDA growth (6.5% versus 7.9%) and a smaller volume decline (1.9% versus 2.2%). BEES GMV growth accelerated to 63% from 53%; non-alcohol revenue growth was 33% versus 34%. Management maintained its 2025 EBITDA growth outlook, according to the Q2 analysis.
Guidance delta
Guidance was maintained. The Q2 analysis says management remained confident in achieving its 2025 EBITDA growth target of 4–8%; it does not report a change to that range.
Key takeaways
- EBITDA increased 6.5% with margin expansion despite a 1.9% volume decline, according to the supplied Q2 analysis.
- Premium brands and non-alcohol offerings remained important growth drivers; non-alcohol beer revenue grew 33%.
- BEES marketplace GMV grew 63% year over year to $785 million, according to the analysis.
- Management expressed confidence in the 2025 EBITDA growth outlook, while volume weakness in China and Brazil remained a headwind.
Management priorities
- Continue investment in megabrands, premium platforms, and innovations across core and beyond-beer categories.
- Expand non-alcohol and low- or zero-sugar offerings, and scale BEES and direct-to-consumer channels.
- Focus on off-trade execution in China and expand the footprint in India; use sports and cultural events for brand activation.
Follow BUD with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Nov 2, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| TD Cowen | Hold | Hold | Maintain | Oct 13, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Oct 5, 2026 |
| Barclays | Equal Weight | Overweight | Downgrade | Jul 27, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 2, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | May 7, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Feb 13, 2026 |
| Goldman Sachs | Buy | Neutral | Upgrade | May 12, 2025 |
| Citigroup | Buy | Neutral | Upgrade | Oct 1, 2024 |
| Exane BNP Paribas | Neutral | Outperform | Downgrade | Jan 12, 2024 |
| Jefferies | Buy | Hold | Upgrade | Jan 10, 2024 |
| B of A Securities | Buy | Neutral | Upgrade | Sep 29, 2023 |
| Deutsche Bank | Buy | Hold | Upgrade | Jun 22, 2023 |
| Redburn Partners | Buy | Neutral | Upgrade | Nov 19, 2021 |
| Argus Research | Hold | Buy | Downgrade | Sep 30, 2021 |
| CFRA | Hold | Hold | Maintain | May 26, 2020 |
| RBC Capital | Outperform | Sector Perform | Upgrade | Mar 12, 2020 |
| Credit Suisse | Neutral | Outperform | Downgrade | Mar 9, 2020 |
| Bryan Garnier | Neutral | Buy | Downgrade | Feb 28, 2020 |
| Redburn | Neutral | Sell | Upgrade | Nov 18, 2019 |
| UBS | Neutral | Buy | Downgrade | Aug 6, 2019 |
| Bank of America | Buy | Neutral | Upgrade | Jul 29, 2019 |
| Macquarie | Neutral | Neutral | Maintain | Mar 1, 2019 |
| Argus | Hold | Buy | Downgrade | Nov 12, 2018 |
| HSBC | Buy | Hold | Upgrade | Jun 4, 2018 |
| Bernstein | Outperform | Market Perform | Upgrade | Mar 12, 2018 |
| Investec | Hold | Buy | Downgrade | Nov 17, 2016 |
| Societe Generale | Hold | Buy | Downgrade | Oct 20, 2016 |
| Kepler Cheuvreux | Buy | Hold | Upgrade | Aug 22, 2016 |
| Susquehanna | Neutral | Positive | Downgrade | Aug 1, 2016 |
| Berenberg | Buy | Hold | Upgrade | Nov 13, 2015 |
| CLSA | Outperform | Underperform | Upgrade | Nov 2, 2015 |
| Ingalls & Snyder, LLC | Buy | Hold | Upgrade | Aug 26, 2015 |
| ING | Buy | Hold | Upgrade | Aug 26, 2015 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jul 31, 2015 |
| Stifel | Buy | Buy | Maintain | Jul 31, 2015 |
| Nomura | Neutral | Buy | Downgrade | Jul 21, 2015 |
| Tigress Financial | Underperform | Neutral | Downgrade | Mar 17, 2015 |
| BTIG Research | Neutral | Buy | Downgrade | Sep 9, 2014 |
| BTIG | Neutral | Buy | Downgrade | Sep 9, 2014 |
| Rabobank | Buy | Hold | Upgrade | Jul 31, 2013 |
| Mirabaud Securities | Accumulate | Neutral | Upgrade | Jul 31, 2013 |
| Mirabaud | Accumulate | Neutral | Upgrade | Jul 31, 2013 |
| KBC Partners | Accumulate | Hold | Upgrade | Jul 31, 2013 |
| Canaccord Genuity | Buy | Hold | Upgrade | Jul 31, 2013 |
| Banco Sabadell | Sell | Buy | Downgrade | Apr 30, 2013 |
Named analyst price targets
Upside is calculated against the persisted previous close $80.38. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Wells Fargo | Chris Carey | $97 | $86.14 | +20.7% | Jul 31, 2026 |
| Morgan Stanley | Analyst unavailable | $84.5 | $80.25 | +5.1% | Jul 1, 2026 |
| Morgan Stanley | Analyst unavailable | $82 | $74.39 | +2.0% | Apr 8, 2026 |
| Evercore ISI | Analyst unavailable | $100 | $79.4 | +24.4% | Feb 13, 2026 |
| Wells Fargo | Analyst unavailable | $85 | $75.81 | +5.7% | Feb 9, 2026 |
| Wells Fargo | Analyst unavailable | $75 | $61.16 | -6.7% | Nov 19, 2025 |
| Jefferies | Edward Mundy | $74 | $59.85 | -7.9% | Sep 29, 2025 |
| Argus Research | Analyst unavailable | $70 | $62.14 | -12.9% | Mar 27, 2025 |
| Morgan Stanley | Sarah Simon | $63 | $49.22 | -21.6% | Jan 9, 2025 |
| Morgan Stanley | Sarah Simon | $73 | $63.66 | -9.2% | Sep 10, 2024 |
| Morgan Stanley | Sarah Simon | $68.5 | $59.96 | -14.8% | Apr 8, 2024 |
| Barclays | Eddie Kim | $65 | $60.2 | -19.1% | Mar 5, 2024 |
| Jefferies | Edward Mundy | $76 | $66.15 | -5.4% | Jan 10, 2024 |
Track every rating change on BUD the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAnheuser-Busch InBev SA/NV (AB InBev) is a global beverage giant involved in the manufacturing, marketing, and retailing of a wide variety of beers, other alcoholic drinks, and soft drinks across the world. The company manages an expansive collection of around 500 beer labels. Its most prominent and globally recognized brands include Budweiser, Corona, and Stella Artois. Additionally, its portfolio features well-known names such as Beck's, Hoegaarden, Leffe, and Michelob Ultra, alongside a host of other popular brands like Aguila, Antarctica, Bud Light, Brahma, Cass, Castle, Castle Lite, Cristal, Harbin, Jupiler, Modelo Especial, Quilmes, Victoria, Sedrin, and Skol. Established in 1366, AB InBev's corporate headquarters are situated in Leuven, Belgium.
Historical context
All BUD earningsConsumer Defensive peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| CHD Church & Dwight Co., Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.2% | +1.2% | Church & Dwight raises sales outlook after strong Q3 organic growth |
| CL Colgate-Palmolive Company | FY2026 Q3 · Calendar Q4 2026 | +4.8% | +2.3% | Colgate-Palmolive: Broad Growth and Margin Expansion in Q3 |
| MDLZ Mondelez International, Inc. | FY2026 Q3 · Calendar Q4 2026 | +10.2% | +3.9% | Mondelez cites volume growth, innovation and productivity as key levers |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the BUD recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:55.686058+00:00
- Polygon adjusted daily market bars · 2026-11-02T12:20:45.917119+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-02T12:20:45.914289+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-02. For educational purposes only; not investment advice.